References
1. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology . Feb 20 2020;58(29):1-464.
2. Liao B, Liu JX, Li ZY, et al. Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes.Allergy . 2018/07/01 2018;73(7):1459-1469.
3. Shah SA, Ishinaga H, Takeuchi K. Pathogenesis of eosinophilic chronic rhinosinusitis. Journal of Inflammation . 2016/04/06 2016;13(1):1-9.
4. Stevens WW, Ocampo CJ, Berdnikovs S, et al. Cytokines in chronic rhinosinusitis. Role in eosinophilia and aspirin-exacerbated respiratory disease. American Journal of Respiratory and Critical Care Medicine . 2015;192(6):682-694.
5. Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers.Journal of Allergy and Clinical Immunology . May 2016;137(5):1449-1456.
6. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. New England Journal of Medicine . 2014;371(13):1189-1197.
7. Zia-Amirhosseini P, Minthorn E, Benincosa LJ, et al. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. Journal of Pharmacology and Experimental Therapeutics . 1999;291(3):1060-1067.
8. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine . 2017;5(5):390-400.
9. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine . 2014;371(13):1198-1207.
10. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. The Lancet . 2012;380(9842):651-659.
11. Kanda A, Kobayashi Y, Asako M, Tomoda K, Kawauchi H, Iwai H. Regulation of interaction between the upper and lower airways in united airway disease. Medical Sciences . Feb 11 2019;7(2):27-35.
12. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. The Journal of Clinical Investigation . 2003;112(7):1029-1036.
13. Kelly EA, Esnault S, Liu LY, et al. Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma.American Journal of Respiratory & Critical Care Medicine . 2017;196(11):1385-1395.
14. Walter S, Ho J, Alvarado R, et al. Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: a systematic review. Clinical & Experimental Allergy . 2020;50(11):1212-1222.
15. Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. Journal of Allergy and Clinical Immunology . 2017;140(4):1024-1031.
16. Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis. Journal of Allergy and Clinical Immunology . 2011;128(5):989-995.
17. Jeimy S, Lam G, Moote WD, Rotenberg B. Mepolizumab for severe chronic rhinosinusitis with polyposis: a case report. Allergy, Asthma and Clinical Immunology . 2017;14(1):92.
18. Snidvongs K, Lam M, Sacks R, et al. Structured histopathology profiling of chronic rhinosinusitis in routine practice.International Forum of Allergy & Rhinology . 2012;2(5):376-385.
19. Van Es SL, Greaves J, Gay S, Ross J, Holzhauser D, Badrick T. Constant quest for quality: digital cytopathology. Journal of Pathology Informatics . 2018;9(13):1-6.
20. Bankhead P, Loughrey MB, Fernandez JA, et al. QuPath: open source software for digital pathology image analysis. Scientific Reports . 2017;7(1):16878.
21. Taqi SA, Sami SA, Sami LB, Zaki SA. A review of artifacts in histopathology. Journal of Oral and Maxillofacial PathologyMay-Aug 2018;22(2):279-279.
22. Protheroe C, Woodruff SA, De Petris G, et al. A novel histologic scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis. Clinical Gastroenterology and Hepatology . 2009;7(7):749-755.
23. Bachert C, Gevaert P, Holtappels G, Johansson SGO, van Cauwenberge P. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. Journal of Allergy and Clinical Immunology . 2001;107(4):607-614.
24. SPSS Statistics . IMB, Corporation; 2019.
25. GraphPad Prism GraphPad Software, Incorporation.; 2019.
26. Menzies-Gow A, Flood-Page P, Sehmi R, et al. Anti–IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. Journal of Allergy and Clinical Immunology . 2003;111(4):714-719.
27. Sonoda Y, Arai N, Ogawa M. Humoral regulation of eosinophilopoiesis in vitro: analysis of the targets of interleukin-3, granulocyte/macrophage colony-stimulating factor (GM-CSF), and interleukin-5. Leukemia . 1989;3(1):14-18.
28. Kita H, Ohnishi T, Okubo Y, Weiler D, Abrams JS, Gleich GJ. Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils.The Journal of Experimental Medicine . 1991;174(3):745-748.
29. Rothenberg ME, Owen WF, Silberstein DS, Soberman RJ, Austen KF, Stevens RL. Eosinophils cocultured with endothelial cells have increased survival and functional properties. Science . 1987;237(4815):645-647.
30. Schwartz C, Willebrand R, Huber S, et al. Eosinophil-specific deletion of IκBα in mice reveals a critical role of NF-κB–induced Bcl-xL for inhibition of apoptosis. Blood . 2015;125(25):3896-3904.
31. Farahi N, Singh NR, Heard S, et al. Use of 111-Indium–labeled autologous eosinophils to establish the in vivo kinetics of human eosinophils in healthy subjects. Blood . 2012;120(19):4068-4071.
32. Weller PF, Spencer LA. Functions of tissue-resident eosinophils.Nat Rev Immunol . 2017;17(12):746-760.
33. Ikeda K, Shiozawa A, Ono N, et al. Subclassification of chronic rhinosinusitis with nasal polyp based on eosinophil and neutrophil.Laryngoscope . 2013;123(11):1-9.
34. Lam K, Schleimer R, Kern RC. The etiology and pathogenesis of chronic rhinosinusitis: a review of current hypotheses. Current Allergy Asthma Respiratory . 2015;15(7):41-50.
35. Ponikau JU, Sherris DA, Kephart GM, et al. Striking deposition of toxic eosinophil major basic protein in mucus: implications for chronic rhinosinusitis. Journal of Allergy and Clinical Immunology . 2005;116(2):362-369.
36. Acharya KR, Ackerman SJ. Eosinophil granule proteins: form and function. Journal of Biological Chemistry . 2014;289(25):17406-17415.
37. Neves JS, Perez SAC, Spencer LA, et al. Eosinophil granules function extracellularly as receptor-mediated secretory organelles.Proceedings of the National Academy of Sciences of the United States of America . 2008;105(47):18478-18483.
38. Lal D, Wright BL, Shim KP, et al. Eosinophil peroxidase, GATA3, and T-bet as tissue biomarkers in chronic rhinosinusitis. Journal of Allergy and Clinical Immunology . 2019;143(6):2284-2287.
39. Rank MA, Ochkur SI, Lewis JC, et al. Nasal and pharyngeal eosinophil peroxidase levels in adults with poorly controlled asthma correlate with sputum eosinophilia. Allergy . 2016/04/01 2016;71(4):567-570.
40. Mukherjee M, Forero DF, Tran S, et al. Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena. European Respiratory Journal . 2020;56(4):2000117.
41. Pouliquen IJ, Kornmann O, Barton SV, Price JA, Ortega HG. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab.International Journal of Clinical Pharmacology and Therapeutics . 2015;53(12):1015-1027.
42. Skrgat S, Girandon Susanj P, Bidovec Stojkovič U, Korosec P. Increase in systemic IL-5 is associated with mepolizumab treatment failure in patients with severe asthma. European Respiratory Journal . 2018;52(62):1132.
43. Tsukamoto N, Takahashi N, Itoh H, Pouliquen I. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin 5 monoclonal antibody, in healthy Japanese male subjects. The American College of Clinical Pharmacology . 2016;5(2):102-108.
44. Coffman RL, Brian WPS, Hudak S, Jackson J, Rennick D. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice.Science . 1989;245(4915):308-310.
45. Kopf M, Brombacher F, Hodgkin PD, et al. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity . 1996;4(1):15-24.
46. Lopez AF, Sanderson CJ, Gamble JR, Campbell HD, Young IG, Vadas MA. Recombinant human interleukin 5 is a selective activator of human eosinophil function. The Journal of Experimental Medicine . 1988;167(1):219-224.
47. Simon HU, Yousefi S, Schranz C, Schapowal A, Bachert C, Blaser K. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. The Journal of Immunology . 1997;158(8):3902-3908.
48. Mukherjee M, Lim HF, Thomas S, et al. Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy.Allergy, Asthma & Clinical Immunology . 2017;13(1):2.
49. Gurram RK, Zhu J. Orchestration between ILC2s and Th2 cells in shaping type 2 immune responses. Cellular & Molecular Immunology . 2019;1(1):1-11.
50. Nussbaum JC, Van Dyken SJ, von Moltke J, et al. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature . 2013;502(7470):245-248.
51. Stein ML, Villanueva JM, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. Journal of Allergy and Clinical Immunology . 2008;121(6):1473-1483.
52. Finkelman FD, Madden KB, Morris SC, et al. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes.The Journal of Immunology . 1993;151(3):1235-1244.
53. Hart TK, Cook RM, Zia-Amirhosseini P, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. Journal of Allergy and Clinical Immunology . 2001;108(2):250-257.
54. Zabeau L, Van der Heyden J, Broekaert D, et al. Neutralizing monoclonal antibodies can potentiate IL-5 signaling. European Journal of Immunology . 2001;31(4):1087-1097.
55. Terada N, Konno A, Natori T, Tada H, Togawa K. Interleukin-5 Preferentially Recruits Eosinophils from Vessels in Nasal Mucosa.Acta Oto-Laryngologica . 1993;113(506):57-60.
56. Yancey SW, Ortega HG, Keene ON, et al. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. Journal of Allergy and Clinical Immunology . 2017;139(4):1167-1175.
57. Blanchet M-R, McNagny KM. Stem cells, inflammation and allergy.Allergy, Asthma & Clinical Immunology . 2009;5(1):13-19.
58. DeMarcantonio MA, Han JK. Nasal polyps: pathogenesis and treatment implications. Otolaryngologic Clinics of North America . 2011;44(3):685-695.
59. Saito H, Matsumoto K, Denburg AE, et al. Pathogenesis of murine experimental allergic rhinitis: a study of local and systemic consequences of IL-5 deficiency. The Journal of Immunology . 2002;168(6):3017-3023.
60. Pretolani M, Goldman M. IL-10: a potential therapy for allergic inflammation? Immunology Today . 1997/06/01/ 1997;18(6):277-280.
61. Klion AD, Law MA, Noel P, Kim Y-J, Haverty TP, Nutman TB. Safety and efficacy of the monoclonal anti–interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood . 2004;103(8):2939-2941.
62. Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials. British Journal of Dermatology . 2020;182(5):1120-1135.
63. Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis. Journal of Allergy and Clinical Immunology . 2014;133(3):921-923.
64. Thomas PS, Yates DH, Barnes PJ. Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. American Journal of Respiratory and Critical Care Medicine . 1995;152(1):76-80.
65. te Velde AA, Huijbens RJF, Heije K, de Vries JE, Figdor CG. Interleukin-4 (IL-4) inhibits secretion of IL-1β, tumor necrosis factor a, and IL-6 by human monocytes. Blood . 1990;76(7):1392-1397.
66. Vannier E, Miller LC, Dinarello CA. Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proceedings of the National Academy of Sciences of the United States of America . 1992;89(9):4076-4080.